The control of feeding behaviour by GLP-1 and exendin-4 has been explored in Zucker obese rats, resulting in a reduction in food intake, with exendin-4 being much more potent than GLP-1
[correct] [smalldesc] India's First Freshly-Activated Glutathione Serum | Targets Pigmentation At Its Source | Fades Dark Spots, Sun Spots &
However, in murine models, exendin-4 demonstrates about 5,500-fold greater potency in improving glucose control, evidenced by the percentage fall in plasma glucose at 1 hour (87)
Available from: Kornelius E, Huang JY, Lo SC, Huang CN, Yang YS
Dyoung, accessed February 2, 2026, Revision of the legislation on supplementary protection certificates for plant protection products (RECAST) | Legislative Train Schedule European Parliament, accessed February 2, 2026, Implementation Of The Pharmaceutical Strategy For Europe And The Intellectual Property Action Plan Part 2 Maiwald GmbH, accessed February 2, 2026, A to Z: Drugs in Highlight Revisited Secerna, accessed February 2, 2026, More Than a Feeling: UPC, Rewriting the Score for Pharma at BIO 2025 Wolters Kluwer, accessed February 2, 2026, Beijing Supreme Peoples Court Upholds Novo Nordisk Semaglutide Patent in China based on Post-Filing Data Eagle IP, accessed February 2, 2026, China delivers a win for Novo Nordisk on semaglutide IP pharmaphorum, accessed February 2, 2026, Chinese drugmakers prep for looming semaglutide generics horizon, accessed February 2, 2026, Ozempics Patent Protection Starts to Expire in 2026

It is worth mentioning that China's FDA said that the application for a marketing license for LIR injection for obesity or overweight indications had been accepted, which was the first time that the weight control indications of GLP-1R agonists have been accepted in China